Capitalization 3.47B 114B P/E ratio 2022
-9.92x
P/E ratio 2023 -4.38x
Enterprise value 1.77B 58.2B EV / Sales 2022
5,182,680,798x
EV / Sales 2023 19,719,958,889x
Free-Float
0%
Yield 2022 *
-
Yield 2023 -
More valuation ratios * Estimated data
Dynamic Chart
1 day-2.91%
1 week+3.44%
Current month+2.19%
1 month+14.06%
3 months+57.07%
6 months+70.26%
Current year+55.76%
More quotes
1 week
46.00
Extreme 46
50.00
1 month
41.15
Extreme 41.15
50.00
Current year
26.65
Extreme 26.65
50.00
1 year
24.60
Extreme 24.6
82.30
3 years
24.00
Extreme 24
92.00
5 years
24.00
Extreme 24
92.00
10 years
24.00
Extreme 24
92.00
More quotes
Manager TitleAgeSince
Founder - 13-07-30
Chief Executive Officer - 13-07-30
Director of Finance/CFO - 22-04-20
Director TitleAgeSince
Chief Executive Officer - 13-07-30
Founder - 13-07-30
Director/Board Member - 22-03-14
More insiders

Other Pharmaceuticals

Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
-2.91%+3.44%-38.05% - 164M
+0.99%-8.89%+87.42%+263.11% 780B
+1.24%-5.21%+67.18%+222.12% 588B
-0.29%+3.35%-9.37%-9.26% 371B
-0.06%-1.90%+13.86%+64.24% 318B
+0.75%+3.32%+20.78%+47.70% 307B
-1.20%+6.76%+1.06%-20.41% 254B
+0.34%+1.88%+14.35%+45.36% 245B
+0.22%-2.40%+6.31%+14.14% 219B
+1.41%+1.76%+43.08%+37.28% 180B
Average +0.19%-0.24%+20.66%+73.81% 326.28B
Weighted average by Cap. +0.62%-2.16%+39.20%+117.43%
See all sector performances
Ratios2022 2023
Net sales 0.53 17.25 0.09 2.95
Net income -274M -8.99B -688M -22.56B
Net Debt -832M -27.27B -1.69B -55.49B
More financial data * Estimated data
Logo BRIM Biotechnology, Inc.
BRIM Biotechnology Inc is a Taiwan-based company mainly engaged in drug discovery and development. The Company's product line is based on the pigment epithelium-derived factor (PEDF) and its derived short-chain polypeptide technology platform for multiple therapeutic areas and indications. The Company has four product candidates, BRM421 Dry Eye, BRM423 Severe Corneal Injury, BRM424 Neurotrophic Keratitis and BRM521 Degenerative Arthritis. BRM421 is primarily indicated for the treatment and repair of dry eye disease (DES) with corneal damage.
Employees
0
More about the company
Date Price Change Volume
24-07-22 46.95 NT$ +0.64% 712 173
24-07-22 46.65 NT$ -2.91% 1,110,093
24-07-19 48.05 NT$ +1.05% 1,047,671
24-07-18 47.55 NT$ -3.06% 1,547,121
24-07-17 49.05 NT$ +4.92% 2,531,827

End-of-day quote Taipei Exchange, July 21, 2024

More quotes